Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IκB kinase inhibitors

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 2, 2007, Pages 734-742

  Newton, Robert ^a   Holden, Neil S ^a   Catley, Matthew C ^b   Oyelusi, Wale ^a   Leigh, Richard ^a   Proud, David ^a   Barnes, Peter J ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; DNA; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; ML 120B; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BRONCHUS MUCOSA; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; DRUG INHIBITION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; ONCOGENE; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE;

CARBOLINES; CELLS, CULTURED; CYTOKINES; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; LUNG; NF-KAPPA B; NIACINAMIDE; PROTEIN KINASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRIDINES; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247222126     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.118125     Document Type: Article

References (38)

1. Adcock IM and Ito K (2004) Steroid resistance in asthma: a major problem requiring novel solutions or a non-issue? Curr Opin Pharmacol 4:257-262.
2. Barnes PJ (2001) Molecular mechanisms of corticosteroids in allergic diseases. Allergy 56:928-936.
3. Barnes PJ (2004) New drugs for asthma. Nat Rev Drug Discov 3:831-844.
4. Barnes PJ and Hansel TT (2004) Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 364:985-996.
5. Barnes PJ and Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071.
6. Bergmann M, Hart L, Lindsay M, Barnes PJ, and Newton R (1998) IkappaBalpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis factor-alpha-induced kappaB-dependent transcription: requirement for an additional activation pathway. J Biol Chem 273:6607-6610.
7. Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, De Alba J, Newton R, Haj-Yahia S, Pun KT, Watts CJ, et al. (2005) Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am J Respir Crit Care Med 172:962-971.
8. Birrell MA, Wong S, Hardaker EL, Catley MC, McCluskie K, Collins M, Haj-Yahia S, and Belvisi MG (2006) IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 69:1791-1800.
9. Bousquet J, Jeffery PK, Busse WW, Johnson M, and Vignola AM (2000) Asthma: from bronchoconstriction to airway inflammation and remodeling. Am J Respir Crit Care Med 161:1720-1745.
10. Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M, Parent L, Pien C, Palombella V, and Adams J (2003) Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 13:2419-2422.
11. Catley MC, Cambridge LM, Nasuhara Y, Ito K, Chivers JE, Beaton A, Holden NS, Bergmann MW, Barnes PJ, and Newton R (2004) Inhibitors of protein kinase C (PKC) prevent activated transcription: role of events downstream of NF-kappaB DNA binding. J Biol Chem 279:18457-18466.
12. Catley MC, Chivers JE, Cambridge LM, Holden N, Slater DM, Staples KJ, Bergmann MW, Loser P, Barnes PJ, and Newton R (2003) IL-1beta-dependent activation of NF-kappaB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. FEBS Lett 547:75-79.
13. Catley MC, Chivers JE, Holden NS, Barnes PJ, and Newton R (2005) Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. Br J Pharmacol 145:114-122.
14. Catley MC, Sukkar MB, Chung KF, Jaffee B, Liao SM, Coyle AJ, Haddad E, Barnes PJ, and Newton R (2006) Validation of the anti-inflammatory properties of smallmolecule IkappaB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol Pharmacol 70:697-705.
15. Chivers JE, Cambridge LM, Catley MC, Mak JC, Donnelly LE, Barnes PJ, and Newton R (2004) Differential effects of RU486 reveal distinct mechanisms for glucocorticoid repression of prostaglandin E release. Eur J Biochem 271:4042-4052.
16. Chivers JE, Gong W, King EM, Seybold J, Mak JC, Donnelly LE, Holden NS, and Newton R (2006) Analysis of the dissociated steroid, RU24858, does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids. Mol Pharmacol 70:2084-2095.
17. Chung KF (2006) Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 7:675-681.
18. Edwards MR, Kebadze T, Johnson MW, and Johnston SL (2006) New treatment regimes for virus-induced exacerbations of asthma. Pulm Pharmacol Ther 19:320-334.
19. Hart LA, Krishnan VL, Adcock IM, Barnes PJ, and Chung KF (1998) Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med 158:1585-1592.
20. Hayden MS and Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:2195-2224.
21. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, et al. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639- 16647.
22. Issa R, Xie S, Lee KY, Stanbridge RD, Bhavsar P, Sukkar MB, and Chung KF (2006) GRO-alpha regulation in airway smooth muscle by IL-1beta and TNF-alpha: role of NF-kappaB and MAP kinases. Am J Physiol 291:L66-L74.
23. Karin M, Yamamoto Y, and Wang QM (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3:17-26.
24. Krappmann D, Wulczyn FG, and Scheidereit C (1996) Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo. EMBO (Eur Mol Biol Organ) J 15:6716-6726.
25. Kwon OJ, Au BT, Collins PD, Baraniuk JN, Adcock IM, Chung KF, and Barnes PJ (1994) Inhibition of interleukin-8 expression by dexamethasone in human cultured airway epithelial cells. Immunology 81:389-394.
26. Li Q, Van Antwerp D, Mercurio F, Lee KF, and Verma IM (1999) Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science (Wash DC) 284:321-325.
27. Nagashima K, Sasseville VG, Wen D, Bielecki A, Yang H, Simpson C, Grant E, Hepperle M, Harriman G, Jaffee B, et al. (2006) Rapid TNFR1 dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ. Blood 107:4266-4273.
28. Nasuhara Y, Adcock IM, Catley M, Barnes PJ, and Newton R (1999) Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells: evidence for additional regulatory steps in κB-dependent transcription. J Biol Chem 274: 19965-19972.
29. Newton R, Hart LA, Stevens DA, Bergmann M, Donnelly LE, Adcock IM, and Barnes PJ (1998a) Effect of dexamethasone on interleukin-1beta-(IL-1beta)- induced nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial cells. Eur J Biochem 254:81-89.
30. Newton R, Seybold J, Kuitert LM, Bergmann M, and Barnes PJ (1998b) Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem 273:32312-32321.
31. Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866.
32. Proud D and Chow CW (2006) Role of viral infections in asthma and chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 35:513-518.
33. Proud D, Sanders SP, and Wiehler S (2004) Human rhinovirus infection induces airway epithelial cell production of human beta-defensin 2 both in vitro and in vivo. J Immunol 172:4637-4645.
34. Schwiebert LM, Stellato C, and Schleimer RP (1996) The epithelium as a target of glucocorticoid action in the treatment of asthma. Am J Respir Crit Care Med 154:S16-S19.
35. Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, and Goeddel DV (1999) Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 10:421-429.
36. Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L, et al. (2006) A selective small molecule IKK{beta} inhibitor blocks NF-{kappa}B mediated inflammatory responses in human fibroblast like synoviocytes, chondrocytes and mast cells. J Pharmacol Exp Ther 317:989-1001.
37. Wouters EF (2004) Management of severe COPD. Lancet 364:883-895.
38. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, and Karin M (1997) The IkappaB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 91:243-252.